Transforming growth factor-β-induced IncRNA-Smad7 inhibits apoptosis of mouse breast cancer JygMC(A) cells

Mayu Arase,¹ Kana Horiguchi,¹,² Shogo Ehata,¹ Masato Morikawa,² Shuichi Tsutsumi,² Hiroyuki Aburatani,² Kohei Miyazono¹,² and Daizo Koinuma¹

¹Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; ²Science for Life Laboratory, Ludwig Institute for Cancer Research, Uppsala University, Uppsala, Sweden; ³Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo

Key words: Apoptosis, breast cancer, long non-coding RNA, Smad7, transforming growth factor-β

Correspondence
Kohei Miyazono, Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Tel: +81-3-5841-3345; Fax: +81-3-5841-3354; E-mail: miyazono@m.u-tokyo.ac.jp

Present address: Research Division, Discovery Pharmacology Department 2, Chugai Pharmaceutical Co. Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan.

Funding Information
Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); Ministry of Health, Labor, and Welfare of Japan; Swedish Cancer Foundation; Mochida Memorial Foundation for the Promotion of Science; Kanae Foundation for Research Abroad; ITO Genboku and SAGARA Chian Memorial Scholarship

Received February 19, 2014; Revised May 12, 2014; Accepted May 15, 2014
Cancer Sci 105 (2014) 974–982
doi: 10.1111/cas.12454

Cancer cells make use of the tumor-promoting aspects of certain cytokines, while inhibiting their tumor-suppressive functions. Inhibition of the apoptotic program is one of the strategies used by cancer cells to continue dysregulated proliferation and tumor formation. The anti-apoptotic Bcl-2 family proteins are often upregulated, while several pro-apoptotic BH3-only proteins are inhibited, either transcriptionally or functionally, through interference with the upstream signaling pathways.¹

Transforming growth factor (TGF)-β family proteins are representative proteins that possess bidirectional roles during tumor progression.² TGF-β exhibits cytostatic effects on various epithelial cells; many cancer cells are refractory to the cytostatic signals induced by TGF-β. Instead, they undergo an epithelial–mesenchymal transition (EMT) in response to TGF-β through induction of several factors, leading to stimulation of tumor migration and invasion.³,⁴ TGF-β also displays both pro-apoptotic and anti-apoptotic effects on epithelial cells in a context-dependent manner. We previously showed that endogenous TGF-β produced by cancer cells plays a protective role in starvation-induced apoptosis of mouse breast cancer JygMC(A) and 4T1 cells through induction of the basic helix-loop-helix protein DEC1 and suppression of the BH3-only protein Bim.⁵ TGF-β also suppresses rapamycin-induced apoptosis of serum-starved human basal-type breast cancer cells (MDA-MB-231 cell line).⁶

High throughput analyses have revealed that only approximately one-quarter of the transcripts are protein coding and that there are many non-coding RNA (ncRNA) in mice.⁷ ncRNA are categorized based on their size and function, and long non-coding RNA (lncRNA) form a family of long transcripts with more than 200 nucleotides.⁸ A limited number of lncRNA have been found to have essential biological functions,⁹ and little is known about whether the majority of lncRNA play a role in cancer cells; this is in contrast to the wealth of information currently available about the roles of microRNA (miRNA) family transcripts in cancer.¹⁰

© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
In the present study, we identified a lncRNA, designated lncRNA-Smad7 during a search for TGF-β-regulated transcripts in mouse mammary gland epithelial cells (NMuMG cell line). Interestingly, we found that lncRNA-Smad7 exhibited an anti-apoptotic effect upon stimulation by TGF-β in the mouse breast cancer cell line JygMC(A).

Materials and Methods

Cell culture. The mouse breast cancer cell lines JygMC(A) and 4T1 were cultured in DMEM containing 10% FBS, 50 units/mL penicillin and 50 µg/mL streptomycin. The mouse mammary epithelial cell line NMuMG was cultured in the above medium supplemented with 10 µg/mL insulin. Cells were grown in a 5% CO₂ atmosphere at 37°C.

Reagents and antibodies. Recombinant TGF-β (TGF-β3) and the TGF-β type I receptor inhibitor SB431542 were purchased from R&D systems (Ixonia, WI, USA) and Sigma-Aldrich (St. Louis, MO, USA), respectively. The following antibodies were used: rabbit anti-phospho-Smad2 (Cell Signaling Technology, Danvers, MA, USA.), mouse anti-α-tubulin (DM1A [Sigma-Aldrich]), mouse anti-Smad2/3 (BD Biosciences,

----

Fig. 1. Cloning of lncRNA-Smad7. (a) RNA-sequencing data from NMuMG cells at the mouse Smad7 gene locus. Black and grey tags are aligned to the sense and antisense genomic sequences, respectively. Vertical axis: mapped tag numbers. Smad7 gene is shown in green, and its exons are shown as boxes (thin boxes, untranslated regions; thick boxes, coding regions) connected by horizontal lines representing introns. (b) Relative positions of the Smad7 gene and EST clones with direction of transcription. Positions of the gene-specific primers used for RACE are shown at the back ends of the blue arrows. (c) Northern blotting of lncRNA-Smad7. NMuMG cells were treated with TGF-β or left untreated for 24 h. Left panel: Ethidium bromide staining of the gel to show the positions of 28S/18S rRNA and equal loading of the samples. Right panel: Northern blotting with an EST sequence (CX230377) as a probe. (d) Schematic representation of the identified lncRNA-Smad7 transcripts. V3 transcript was identified by quantitative RT-PCR (qRT-PCR) analysis of JygMC(A) and confirmed by sequencing of the PCR product. V3 had a longer exon 2 and a shorter exon 3 than V2 transcript.
IncRNA-Smad7 inhibits apoptosis

Franklin Lakes, NJ, USA), rabbit anti-PARP (Cell Signaling Technology), mouse anti-E-cadherin (BD Biosciences), mouse anti-N-cadherin (BD Biosciences) and rabbit anti-fibronectin (Sigma-Aldrich).

Northern blotting. A specific probe to detect IncRNA-Smad7 was made with the DIG T7 RNA Labeling Kit (Roche Diagnostics, Rotkreuz, Risch, Switzerland) using an EST sequence (CX230377), which was cloned into pBlueScript SK vector as a template. Northern blotting was performed with the DIG Northern Starter Kit (Roche Diagnostics). The probed membrane was washed twice with 2 × SSC (300 mM NaCl, 30 mM sodium citrate, pH 7.0) with 0.1% SDS for 5 min at room temperature and twice with 0.1 × SSC with 0.1% SDS for 15 min at 68°C. HRP-conjugated anti-digoxigenin was used to detect the hybridized probe by chemiluminescent imaging with a lumino-image analyzer (LAS-4000 [GE Health Care, Hino, Tokyo, Japan]).

Rapid amplification of cDNA ends. 5' and 3' rapid amplification of cDNA ends (RACE) were performed using the SMARTer RACE cDNA Amplification Kit (TakaraBio, Otsu, Shiga, Japan) in accordance with the manufacturer's protocol. Gene-specific primers used for 5' and 3' RACE were CAGTGCCGCTGGA GACCAGAAGAATCCAG and CTGGATTCCTCGTCTCCCA CGGCACCTG, respectively. Following the identification of the 5' or 3' ends of the RACE transcripts, we obtained clones of the expected size for IncRNA-Smad7 by PCR using a set of primers designed to hybridize to each end of the transcript.

Immunoprecipitation and immunoblotting. Lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCl pH 8.0, 5 mM EDTA and COMPLETE EDTA-free protease inhibitor cocktail [Roche Diagnostics]) was used for cell lysis. SDS-gel electrophoresis and immunoblotting were performed as described previously, (13) using the LAS-4000. Quantification of the immunoblotting images was performed using Image-J software (National Institute of Health, Bethesda, MD, USA).

Adenoviral expression vectors. Ad-LacZ and Ad-Incrna-Smad7 (variant 1) were prepared using the pAd-CMV-V5 vector (TakaraBio). Crude viral lysate was purified using ViralKit Adeno -4 (VIRAPUR, San Diego, CA, USA). Titration was performed with the Adeno-X Rapid Titer Kit (BD Biosciences).

RNA interference. We used two different siRNA against IncRNA-Smad7 (1: 5'-AAGAGUUGAGUCGCCAACUAGG-3' and 2: 5'-GGGAAGAAGACAGCAGUCAAGAGAAG-3') designed with the BLOCK-it RNAi Designer (Life Technologies, Carlsbad, CA, USA). Control siRNA was purchased from Life Technologies (Cat. 12935–112, sequence not available). siRNA were introduced into JygMC(A) cells with Lipofectamine 2000 reagent (Life Technologies) according to the manufacturer’s instructions. The final concentration of siRNA in the culture medium was 60 nM.

RNA sequencing. Total RNA (10 μg) was purified from NMuMG cells either stimulated with TGF-β or left untreated for 24 h and then polyA selected with Dynabeads Oligo(dT)25 (Life Technologies). Libraries were made and directionally sequenced with the Illumina Genome Analyzer Ix. One lane of the Illumina flow cell was used for each library to obtain sequencing data. Sequenced raw tags were directionally aligned to either mm9 transcripts or to the reported genomic loci of IncRNA (mm9) (14) by TopHat,(15) and differential gene expression calls were performed with the cuffdiff function of Cufflinks. (16) Note that the reported IncRNA formed multi-exonic structures that were not fully defined. Therefore, we counted all of the mapped tags in the correct direction on each gene locus for the calculation above. The resultant "fragments per kilobase of exon per million mapped fragments sequenced" (FPKM) values thus potentially contain the sequence tags mapped to introns.

Apoptosis assay. Cells were treated as described previously. (4,5) The method is outlined in detail in the online Supporting Information.

Phalloidin staining. Phalloidin staining was performed as described with modification (available in online Supporting Information). (17)

Tumor xenograft assay. Four-week-old female Balb/c nude mice were inoculated subcutaneously with 1.0 × 106 siRNA- transfected JygMC(A) cells. Tumor volume was measured every other day and calculated using the following formula: [(major axis) × (minor axis)]2/2. All animal experiments were performed in accordance with the policies of the animal ethics committee of the University of Tokyo.

Statistical analysis. Repeated measures ANOVA was used for multiple data comparisons.

Accession numbers. Full nucleotide sequences of IncRNA-Smad7 are available from the DNA Data Bank of Japan (AB904933 and AB904934).

Method for RNA isolation, quantitative real-time PCR and primer sequences for quantitative RT-PCR (qRT-PCR) are available from the online Supporting Online.
Results

Identification of lncRNA-Smad7 as a target gene of transforming growth factor-β. We performed RNA sequencing to quantitatively screen for lncRNA downstream of TGF-β signaling in NMuMG cells. To this end, we calculated changes in the expression of the reported lncRNA after the cells were treated with TGF-β (Table S1). We focused on a TGF-β-induced and highly expressed lncRNA transcribed from an upstream and antisense strand of the Smad7 gene, which encodes a known target and inhibitor of TGF-β signaling (Fig. 1a). Distribution of the sequenced tags fell within two spliced EST, CX230377 and CF356854, and did not overlap with Smad7 (Fig. 1b). Northern blotting using CX230377 as a probe resulted in the detection of an approximately 3-kb transcript that was strongly induced by TGF-β treatment (Fig. 1c). We then cloned the transcript by RACE using gene-specific primers designed from CX230377 sequences and identified two transcripts, which we designated lncRNA-Smad7 V1 (2685 bp) and V2 (2801 bp) (Fig. 1d). In addition, variant 3 of lncRNA-Smad7 (V3) was identified through RT-PCR analysis of JygMC(A) cells (data not shown). There were only short open reading frames (ORF) encoding <97 amino acids in lncRNA-Smad7. These ORF did not have a canonical Kozak sequence (data not shown).

We next analyzed the expression of lncRNA-Smad7 in 4T1 and JygMC(A) mouse breast cancer cells by qRT-PCR.

![Fig. 3. Knockdown of lncRNA-Smad7 induces apoptosis of JygMC(A) cells.](image-url)

(a) Effect of siRNA for lncRNA-Smad7 in JygMC(A) cells. Cells were transfected with the indicated siRNA and stimulated with 1 ng/mL TGF-β for 48 h after transfection. silncRNA-1 was used for knockdown of all variants of lncRNA-Smad7, while silncRNA-2 was designed for knockdown of V1 only. Relative expression of lncRNA was determined as in Figure 2a. NTF, no transfection control; siNC, negative control siRNA. (b) Live-cell counting of JygMC(A) cells treated with siRNA for lncRNA-Smad7. Cells were transfected with siRNA as indicated and treated with 1 ng/mL TGF-β or 10 μM SB431542 with serum starvation 48 h after transfection. Live cells were counted using TC20 (BioRad, Hercules, California, USA) after 48 h. (c) TUNEL staining of JygMC(A) cells treated with siRNA for lncRNA-Smad7. Cells were treated as in (b). TUNEL, red; DAPI, blue. (d) The percentage of TUNEL-positive cells among DAPI-positive cells was determined. Error bars: standard deviations. *P < 0.05, **P < 0.001.

![Fig. 4. Forced expression of lncRNA-Smad7 partially inhibits apoptosis of JygMC(A) cells.](image-url)

(a) Cells were infected with either adenoviral lncRNA-Smad7 expression vector (Ad-lncRNA-Smad7) or Ad-LacZ as a control. Twelve hours after infection, cells were serum starved and treated with 1 ng/mL TGF-β or 10 μM SB431542 (SB) for 48 h. Expression of lncRNA-Smad7 was determined by quantitative RT-PCR (qRT-PCR). (b) Effect of Ad-lncRNA-Smad7 on cleaved PARP level was determined by immunoblotting. Cells were treated as in (a) and lysed for SDS-PAGE. The bottom graph shows quantification of cleaved PARP normalized to α-tubulin. **P < 0.001. (c) TUNEL staining of JygMC(A) cells. Cells were treated as in (a). TUNEL, red; DAPI, blue. (d) The percentage of TUNEL-positive cells among DAPI-positive cells was determined. Error bars: standard deviations.
Expression of lncRNA-Smad7 was induced early after stimulation with TGF-β and continued for 48 h (Fig. 2a). Upregulation of lncRNA-Smad7 by TGF-β was observed in two other mouse mammary gland cell lines, EpH4 and EpRas (Fig. S1). Both 4T1 and JygMC(A) cells secrete endogenous TGF-β, and basal expression of lncRNA-Smad7 was inhibited by the TGF-β type I receptor kinase inhibitor SB431542 (Fig. 2b). These results suggest that lncRNA-Smad7 is expressed in several mouse mammary gland epithelial cell lines and that TGF-β upregulates its expression in breast cancer cells.

**lncRNA-Smad7 inhibits apoptosis of breast cancer cells induced by transforming growth factor-β.** We next knocked down the expression of lncRNA-Smad7 by two different siRNA; that is, silncRNA-1 and silncRNA-2 (Fig. 3a). silncRNA-1 was designed to knock down all three variants, while silncRNA-2 was designed to knock down only V1. As shown in Figure 3a, expression of lncRNA-Smad7 was repressed efficiently by silncRNA-1 and moderately by silncRNA-2 in JygMC(A) cells. We found that live cell counts were decreased by silncRNA-1 in vitro (Fig. 3b). JygMC(A) cells underwent apoptosis upon serum starvation, and the apoptosis was induced by SB431542 and inhibited by TGF-β. The role of lncRNA-Smad7 in TGF-β-induced anti-apoptosis was then evaluated. Inhibition of apoptosis by TGF-β was partially cancelled by suppression of lncRNA-Smad7 expression, as determined by TUNEL staining (Fig. 3c,d). Consistent with the silencing efficiencies, the effects of silncRNA-2 were less marked than those of silncRNA-1 (Fig. 3c,d). Cleaved PARP levels in TGF-β-stimulated cells were also increased following treatment with silncRNA-1 and silncRNA-2 (Fig. 3e).

The adenoviral lncRNA-Smad7 expression vector (Ad-lncRNA-Smad7) was then constructed to examine its effect on apoptosis. Expression of exogenous lncRNA-Smad7 was confirmed by qRT-PCR and compared with endogenous expression levels and with a sample without reverse transcription (Fig. 4a and data not shown). Partial inhibition by Ad-lncRNA-Smad7 of cleaved PARP expression was observed in both TGF-β-stimulated and TGF-β-unstimulated cells (Fig. 4b). The numbers of TUNEL-positive cells induced by SB431542 treatment were reduced by forced expression of lncRNA-Smad7 (Fig. 4c,d), which suggests that lncRNA-

---

### Figure 5

In lncRNA-Smad7 does not regulate phospho-Smad2 levels or TGF-β-induced EMT. (a) JygMC(A) cells were transfected with siRNA as indicated and stimulated with TGF-β for 48 h. Phospho-Smad2 and total Smad2/3 levels were determined by immunoblotting (top panel). The bottom graph shows quantification of phospho-Smad2 normalized to total Smad2/3. n.s.: not significant. (b) Effect of siRNA for lncRNA-Smad7 on Smad7 expression evaluated by quantitative RT-PCR (qRT-PCR). Transfected cells were stimulated with TGF-β for 48 h. NTF, no transfection; error bars, standard deviations. (c) NMuMG cells were reverse-transfected with siRNA as indicated. Twelve hours later, cells were stimulated with TGF-β for 24 h and fixed. F-actin formation was evaluated by phalloidin staining. (d) NMuMG cells were treated as in (c) and expression of EMT marker proteins was determined by immunoblotting.
Smad7 acts as an anti-apoptotic factor downstream of TGF-β signaling. **Effect of lncRNA-Smad7 on transforming growth factor-β-Smad signaling pathway and transforming growth factor-β-induced epithelial-mesenchymal transition.** lncRNA have several modes of function, including neutralizing miRNA and inhibiting transcription of target genomic regions.[8] Therefore, we next evaluated the effect of siRNA for lncRNA-Smad7 on the TGF-β-Smad signaling pathway. Knockdown of lncRNA-Smad7 did not change phospho-Smad2 expression in JygMC(A) cells (Fig. 5a). Moreover, expression of Smad7 by TGF-β stimulation was minimally inhibited by the siRNA for lncRNA-Smad7 (Fig. 5b). We then evaluated the effect of silncRNA on TGF-β-induced EMT in NMuMG cells. Actin stress fiber formation by TGF-β stimulation was not inhibited by the silncRNA, and silncRNA-2 showed a mild F-actin-inducing effect in the absence of TGF-β (Fig. 5c). Both downregulation of E-cadherin and induction of fibronectin and N-cadherin by TGF-β were not affected by the silncRNA (Fig. 5d). These results suggest that lncRNA-Smad7 does not have a marked effect on TGF-β signaling in general but does regulate anti-apoptosis-specific effects. Upregulation of Bhlhe40 (encoding the anti-apoptotic DEC1 protein) and inhibition of Bcl2l11 (encoding the pro-apoptotic BH3-only protein Bim) through downregulation of Foxc1 have been demonstrated as mechanisms of TGF-β-induced apoptosis in breast cancer cells.[4,5] We examined the effect of lncRNA-Smad7 on the mRNA levels of these molecules, but the changes in their expression profiles could not explain the anti-apoptotic function of lncRNA-Smad7 (Fig. S2). We also searched for other pro-apoptotic and anti-apoptotic factors whose mRNA and protein expression levels were regulated by lncRNA-Smad7, but we were not able to identify any definite targets (data not shown).

**Role of lncRNA-Smad7 in xenografted tumor formation.** Finally, we examined whether lncRNA-Smad7 affects the tumor-forming ability of JygMC(A) cells. Tumor size was periodically measured after subcutaneous inoculation of siRNA-transfected JygMC(A) cells into mice. As shown in Figure 6, knockdown of lncRNA-Smad7 resulted in reduced tumor size, suggesting impaired graft survival in the absence of lncRNA-Smad7 (Fig. 6a,b).

**Discussion**

In the present study, we identified lncRNA-Smad7 through a search for TGF-β-regulated transcripts in mouse mammary NMuMG cells. lncRNA-Smad7 is located adjacent to the mouse Smad7 gene and is strongly upregulated by TGF-β in the mouse mammary gland epithelial cells and mouse breast cancer cells. lncRNA-Smad7 appears to function as a downstream anti-apoptotic factor of TGF-β in the mouse breast cancer cell line JygMC(A) without affecting activation of Smad2 and induction of EMT.

lncRNA regulate gene expression through several mechanisms in cancer.[10,11] The lncRNA HOTAIR was identified in breast tumors as a poor prognosis marker that induces alteration of Polycomb-regulated histone H3K27 modification and gene expression.[10,19] Subsequently, the presence of HOTAIR was reported to be associated with the prognosis of nasopharyngeal carcinoma and esophageal cancer.[20,21] Zhang et al.[22] reported that the lncRNA-RoR inhibited translation of p53 and apoptosis in MCF-7 breast cancer cells. Importantly, lncRNA-RoR also functions as a miRNA sponge to inhibit a set of miRNA in human ES cells, suggesting that even a single type of lncRNA has several modes of action.[23] Other lncRNA are related to the pathogenesis of breast cancers. The ATM target gene lncRNA-JADE protects MCF7 cells from several DNA-damaging drugs to maintain tumor formation.[24] In addition, Hu et al.[25] analyzed lncRNA expression signatures during the twist-induced EMT of MCF10A cells.

We identified lncRNA-Smad7 as a new anti-apoptosis factor in mouse breast cancer cells, although we could not identify the regulatory mechanism of apoptosis induced by lncRNA-Smad7. In principle, siRNA-based loss-of-function analyses of lncRNA may not be an ideal means of evaluating their transcriptional or epigenomic regulatory mechanisms. Therefore, we cannot conclude that lncRNA-Smad7 does not regulate transcription of the adjacent Smad7 and other genes. In contrast, the anti-apoptotic activity of lncRNA-Smad7 observed in our siRNA experiments could instead be executed through post-transcriptional regulatory mechanisms. Determining the effect of lncRNA-Smad7 on Smad7 expression will be an important topic for future analysis, because Smad7 sensitizes MCF7 cells to IRF1-induced apoptosis.[26]

Our present analysis revealed that lncRNA-Smad7 was widely expressed in mouse mammary epithelial cells and mouse breast cancer cells. This transcript was previously found in a list yielded by transcriptome analyses of mouse ES cells,[14] suggesting that it is broadly expressed in many mouse cell types and tissues. Transcriptional upregulation of lncRNA-Smad7 by TGF-β would also be a general mechanism in mice, because the transcriptional start site of lncRNA-Smad7 is close to Smad7, a well-known target of TGF-β/Smad signaling. Guttmann et al.[27] included this lncRNA in their loss-of-function screening based on the good conservation among species, and...
In LncRNA-Smad7 was designated as linc1316 in their list (table 1). However, our efforts to find a human ortholog by using our unpublished RNA-sequencing data from several TGF-β-treated human epithelial cell lines and cancer cell lines were unsuccessful (data not shown). Moreover, a BLAST-based search for LncRNA-Smad7-like genomic sequences showed that only approximately 400 nucleotides out of the 3-kb mouse LncRNA-Smad7 are conserved upstream of SMAD7 in humans, which was in contrast to the high conservation between mice and rats (data not shown). Therefore, LncRNA-Smad7 appears to be a rodent-specific transcript. However, there is still a possibility that the identified 400-bp region in humans might be transcribed in a limited condition and has functions similar to that of mouse LncRNA-Smad7 in human breast cancers.

Comprehensive analysis of transcriptional regulation of the many target genes of TGF-β through ChIP-sequencing or ChIP-chip analyses have been performed in several cancer cell lines and mouse cancer cell lines from different cell types are available. In the case of LncRNA, Zhou et al. reported a list of TGF-β-Smad3 target LncRNA expressed during renal inflammation and fibrosis. However, the lack of knowledge about the function of non-coding transcripts often limits the utility of these types of data. Our findings, together with the findings of low conservation of LncRNA among species, suggest that determination of the roles of each non-coding transcript is required to understand their relevance to cancer biology.

Acknowledgements

The authors are grateful to Kaori Shiina and Keiko Yuki for technical assistance, as well as to members of the Miyazono Laboratory for discussion and advice. This research was supported by KAKENHI (grants-in-aid for scientific research on Innovative Areas [Integrative Research on Cancer Microenvironment Network; 22112002, K.M.], Scientific Research [S] [20221009, H.A.], [C] [24501311, D.K.] and [B] [24390700, K.M.]) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) and a grant from the Ministry of Health, Labor, and Welfare of Japan (D.K.). This study was performed in part as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct) from MEXT, and a grant from the Swedish Cancer Foundation (No. 100452, K.M.). D.K. is supported by a grant from the Mochida Memorial Foundation for Medical and Pharmaceutical Research. M.A. is supported by grants from the Ishidzu Shun Memorial Scholarship and the Japan Society for the Promotion of Science. M.M. is supported by the Kanae Foundation for Research Abroad and the ITO Genboku and SAGARA Chian Memorial Scholarship.

Disclosure Statement

The authors have no conflict of interest to declare.
Supporting Information

Additional supporting information may be found in the online version of this article:

Table S1. lncRNA regulated by transforming growth factor (TGF)-β

Fig. S1. Upregulation of lncRNA-Smad7 in mouse mammary gland cell lines.

Fig. S2. Effects of siRNA for lncRNA-Smad7 on expression of DEC1 and Bim.